- Advertisement -
- Advertisement -

Related

Concentration: A Double-Edged Sword

Latest Report

- Advertisement -

Stockholm (HedgeNordic) – A focused, concentrated portfolio offers a much higher chance of beating the market, but high concentration also carries substantial risks. Max Mitteregger’s unconventional investing approach – characterized by high portfolio concentration, bearish stance on equities, high variability in net market exposure, and active risk-taking in biotech stocks – has not paid off so far this year for his long/short equity fund. Mitteregger’s Gladiator Fond is down 33.3 percent in the first seven months of 2021 after booking a loss of 17.9 percent in July alone.

“Unfortunately, the fund had a very weak development during July and fell 17.88 percent,” writes Mitteregger in a monthly update to investors. “There are several reasons behind the extremely weak development,” adds the Stockholm-based money manager, pointing out that the largest negative contributor was Swedish biotech Oncopeptides. In late July, the U.S. FDA issued a safety alert citing trial data showing an increased risk of death associated with Pepaxto, the company’s only marketed drug, used in combination with dexamethasone to treat multiple myeloma. Earlier that month, the FDA put a partial clinical hold on all clinical trials of the biotech company’s multiple myeloma drug candidate after trial data found large differences in overall survival in pre-specified subgroups.

The share price of Oncopeptides decreased by 54 percent during the month of July. “After an unclear and much-debated study result,” the share price of Oncopeptides continued to drop in July, writes Mitteregger. However, Gladiator Fond increased its stake in Oncopeptides during the month, “as I believe that the negative price movement has been overexaggerated, with a large more detailed study data coming in early September,” writes the fund manager.

“I believe that the negative price movement has been overexaggerated, with a large more detailed study data coming in early September.”

Gladiator Fond performed strongly in the post-financial-crisis period, partly due to Mitteregger’s skill at identifying high risk-reward opportunities in the biotech space. “I need to make some big bets to generate good returns,” the portfolio manager told HedgeNordic in 2019. “If everyone is saying a biotech’s value can go to zero, but I see a 75 percent chance of making four times the investment, I can afford to allocate six or seven percent of capital to that bet.” In 2021 and July in particular, the biotech-focus has detracted from the fund’s performance.

In July, two other biotech stocks detracted from Gladiator Fond’s returns. “Another of the fund’s large holdings (Camurus) came with a slightly weaker report but maintained its full-year forecast,” writes Mitteregger. Even so, the share price of the Swedish research-based pharmaceutical and biotechnology company fell by about 16 percent. “Hansa Biopharma fell 23% during the month without any major news (the holding was sold in July) and the fund’s largest holding, Astra Zeneca, fell by 4%,” adds Mitteregger.

“During the year, the fund held a number of short positions which, despite extremely high valuations, continued to rise.”

Gladiator Fond tends to maintain a concentrated portfolio of about ten long positions and reduces the market exposure mostly with OMX30 futures or put options on the index, in addition to a few individual short positions. Mitteregger’s short positions in 2021 have not paid off either. “During the year, the fund held a number of short positions which, despite extremely high valuations, continued to rise,” says Mitteregger. “During July, for example, EQT rose by 30% (up 96% on the year) and Balder 10% (up 65% on the year), also the other short-term holdings that the fund has went up in July.”

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest Articles

Record Month for Tidan in Priced-to-Perfection Credit Market

Tidan Fund, a Stockholm-based hedge fund specialising in opportunities across corporate capital structures, marked its four-year anniversary in September with its strongest month on...

Zetterquist Leads Antiloop’s Reset as Cygnus and Atlas Gain Momentum

After helping build and later steer the operations of fund boutique Norron, first as COO and then as CEO, Alexander Zetterquist is embarking on...

From Running Laps to Running Capital: Ex-Taiga Analyst at DNB

After nine years as an analyst at equity long/short hedge fund Taiga Fund, Øystein Kvaerner has joined DNB Asset Management to launch a new...

Nordic Hedge Funds Wrap Up Strong Third Quarter

Nordic hedge funds continued their strong run of performance since May, advancing an additional 1.7 percent on average in September – the industry’s second-best...

DNB’s Stable Alpha Goes DACH

DNB Asset Management has managed its in-house multi-manager, multi-strategy fund platform since early 2020. After a period of muted performance in its early years,...

Opportunities Lie Beneath Aggregate Credit Spreads

Credit spreads across the United States and Europe have tightened to historically low levels, leaving limited reward for simply holding long credit positions. This...

Allocator Interviews

In-Depth: High Yield

Voices

Request for Proposal

- Advertisement -
HedgeNordic
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.